Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Invasive candidiasis (IC) is an important healthcare-related infection, with increasing incidence and a crude mortality exceeding 50%. Numerous treatment options are available yet comparative studies have not identified optimal therapy. METHODS: We conducted an individual patient-level quantitative review of randomized trials for treatment of IC and to assess the impact of host-, organism-, and treatment-related factors on mortality and clinical cure. Studies were identified by searching computerized databases and queries of experts in the field for randomized trials comparing the effect of ≥2 antifungals for treatment of IC. Univariate and multivariable analyses were performed to determine factors associated with patient outcomes. RESULTS: Data from 1915 patients were obtained from 7 trials. Overall mortality among patients in the entire data set was 31.4%, and the rate of treatment success was 67.4%. Logistic regression analysis for the aggregate data set identified increasing age (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.00-1.02; P = .02), the Acute Physiology and Chronic Health Evaluation II score (OR, 1.11; 95% CI, 1.08-1.14; P = .0001), use of immunosuppressive therapy (OR, 1.69; 95% CI, 1.18-2.44; P = .001), and infection with Candida tropicalis (OR, 1.64; 95% CI, 1.11-2.39; P = .01) as predictors of mortality. Conversely, removal of a central venous catheter (CVC) (OR, 0.50; 95% CI, .35-.72; P = .0001) and treatment with an echinocandin antifungal (OR, 0.65; 95% CI, .45-.94; P = .02) were associated with decreased mortality. Similar findings were observed for the clinical success end point. CONCLUSIONS: Two treatment-related factors were associated with improved survival and greater clinical success: use of an echinocandin and removal of the CVC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational studies do, however, suggest that mortality may increase after intervals exceeding 3-5 hours from hospital arrival and/or sepsis recognition (98,111,119,120).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [120]
In the citing paper
“Two RCTs have been published (119, 120); one failed to achieve a difference in time-to-antimicrobials between arms (120) and the other found no significant difference in mortality despite a 90-minute difference in median time interval to antimicrobial administration (119).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [120]
In the citing paper
“Source control of infectious foci was associated with improved survival in recent observational and cluster randomized studies (120,263,264).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [120]
In the citing paper
“Treatment with FLC often fails despite isolates being drug susceptible when tested in vitro, and rates of persistent candidemia are often higher in patients treated with FLC rather than with echinocandins 58 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [58]
In the citing paper
“The most recent Infectious Disease Society of America (IDSA)125 and European guidelines126,127 recommend echinocandins as first-line initial treatment for most invasive candidiasis in both neutropenic and non-neutropenic patients prior to identification to the species level due to their broad spectrum of activity, favorable side effect profile, mortality benefit, and the increasing incidence of az”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [130]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 3×
“mon cause of nosocomial bloodstream infection [1–4].”
BackgroundMermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Blacklow, N. R., Gorbach, S. L., & Bartlett, J. G. (1992) · Cited by 2,753
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578
Biofilms and Device-Associated Infections
Donlan, R. M. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010226 · Cited by 1,504
Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada
Kumar, A. (2009) · JAMA · doi:10.1001/jama.2009.1496 · Cited by 1,425
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Candida biofilms and their role in infection
Douglas, L. J. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(02)00002-1 · Cited by 1,150
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055 · cited 1×
“Catheters, like other medical devices, can serve as a substrate for Candida biofilm infection, which exhibits a drug-resistant phenotype [60, 61], necessitating biofilm extirpation for treatment success [62, 63].”
BackgroundRex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationPittet, D. (1994) · JAMA · doi:10.1001/jama.1994.03510440058033 · Cited by 926
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Self-citationHospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationDevice-Associated Nosocomial Infections in 55 Intensive Care Units of 8 Developing Countries
Rosenthal, V. D., Maki, D. G., Salomao, R., Moreno, C. Á., Mehta, Y., Higuera, F., Cuellar, L. E., Arikan, Ö. A., Abouqal, R., Leblebicioglu, H., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00007 · Cited by 544
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationMorgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385 · cited 1×
“Moreover, longitudinal studies have detected a global shift in epidemiology toward non-albicans Candida species, particularly Candida glabrata [14–22].”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
Risk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369
Pachl, J., Svoboda, P., Jacobs, F., Vandewoude, K., van der Hoven, B., Spronk, P., Masterson, G., Malbrain, M., Aoun, M., Garbino, J., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503428 · Cited by 307
Predictors of Adverse Outcome in Cancer Patients with Candidemia
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00030-8 · Cited by 295
Self-citationSaravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 293
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., & Rodriguez-Noriega, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00409-07 · Cited by 284
Fourrier, F., Dubois, D., Pronnier, P., Herbecq, P., Leroy, O., Desmettre, T., Pottier-Cau, E., Boutigny, H., Di Pompéo, C., Durocher, A., et al. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000171537.03493.b0 · Cited by 265
Micafungin: A New Echinocandin
Chandrasekar, P. H., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/501020 · Cited by 256
Self-citationIntravascular Catheter Exchange and Duration of Candidemia
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., Serody, J., Edwards, J. E., Washburn, R. G., NIAID Mycoses Study Group, & Candidemia Study Group (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.4.994 · Cited by 252
Self-citationNucci, M., Anaissie, E., Betts, R. F., Dupont, B. F., Wu, C., Buell, D. N., Kovanda, L., & Lortholary, O. (2010) · Clinical Infectious Diseases · doi:10.1086/653935 · Cited by 228
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D., Chawla, V., Young, J., & Hadley, S. (2008) · Clinical Infectious Diseases · doi:10.1086/529435 · Cited by 223
Posaconazole: A Broad-Spectrum Triazole Antifungal Agent
Nagappan, V., & Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/523576 · Cited by 223
Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Self-citationInvasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis
Shorr, A. F., Sherner, J. H., Jackson, W. L., & Kollef, M. H. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000149852.32599.31 · Cited by 200
Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin
Vazquez, J. A., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/505204 · Cited by 199
Self-citationTreatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181
Alonso-Echanove, J., Edwards, J. R., Richards, M. J., Brennan, P., Venezia, R. A., Keen, J., Ashline, V., Kirkland, K., Chou, E., Hupert, M., et al. (2003) · Infection Control & Hospital Epidemiology · doi:10.1086/502160 · Cited by 178
Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.
Playford, E. G., Marriott, D. J. E., Nguyen, Q. A., Chen, W., Ellis, D., Slavin, M. A., & Sorrell, T. C. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181760f42 · Cited by 175
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death
Slavin, M. A., Sorrell, T. C., Marriott, D., Thursky, K. A., Nguyen, Q., Ellis, D. H., Morrissey, C. O., Chen, S. C. A., & on behalf of the Australian Candidemia Study, A. S. F. I. D. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq053 · Cited by 162
Zaoutis, T. E., Goyal, M., Chu, J. H., Coffin, S. E., Bell, L. M., Nachamkin, I., McGowan, K. L., Bilker, W. B., & Lautenbach, E. (2005) · PEDIATRICS · doi:10.1542/peds.2004-1289 · Cited by 154
STEINBERG, K. K., Smith, S. J., Stroup, D. F., Olkin, I., Lee, N. C., Williamson, G. D., & Thacker, S. B. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009051 · Cited by 150
Garnacho-Montero, J., Aldabó-Pallás, T., Palomar-Martínez, M., Vallés, J., Almirante, B., Garcés, R., Grill, F., Pujol, M., Arenas-Giménez, C., Mesalles, E., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1204-7 · Cited by 150 · cited 1×
“parapsilosis when treated with an echinocandin in these trials, which in the current analysis may be explainable by the organisms’s relatively lower virulence [18, 42, 44].”
BackgroundRisk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia
Uzun, O., Ascioglu, S., Anaissie, E. J., & Rex, J. H. (2001) · Clinical Infectious Diseases · doi:10.1086/320757 · Cited by 138
Self-citationSecular trends in candidemia-related hospitalization in the United States, 2000–2005
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591033 · Cited by 137
van Kasteren, M. E. E., Manniën, J., Kullberg, B. J., de Boer, A. S., Nagelkerke, N. J. D., Ridderhof, M., Wille, J. C., & Gyssens, I. C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki374 · Cited by 135
Self-citationPappas, P. G., Rotstein, C. M. F., Rf, B., Nucci, M., Talwar, D., Waele, J. J. D., Jm, D. L. V. V., Dupont, B., Horn, D., Ostrosky‐Zeichner, L., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 130
Self-citationBassetti, M., Trecarichi, E. M., Righi, E., Sanguinetti, M., Bisio, F., Posteraro, B., Soro, O., Cauda, R., Viscoli, C., & Tumbarello, M. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.01.005 · Cited by 122
Candidemia in a Tertiary Care Hospital: Epidemiology and Factors Influencing Mortality
Valle, H. A., Acha, O., García-Palomo, J. D., Fariñas-Álvarez, C., Fernández-Mazarrasa, C., & Fariñas, M. C. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0890-x · Cited by 113
Jacobson, B. A., Panka, D. J., Nguyen, K.-A., Erikson, J., Abbas, A. K., & Marshak‐Rothstein, A. (1995) · Immunity · doi:10.1016/1074-7613(95)90179-5 · Cited by 109
Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis
Gafter‐Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., & Paul, M. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1011 · Cited by 97
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection
Klevay, M. J., Ernst, E. J., Hollanbaugh, J. L., Miller, J. G., Pfaller, M. A., & Diekema, D. J. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.10.001 · Cited by 73
Horn, D. L., Ostrosky-Zeichner, L., Morris, M. I., Ullmann, A. J., Wu, C., Buell, D. N., Kovanda, L. L., & Cornely, O. A. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0843-0 · Cited by 69
Ventilator-Associated Pneumonia
Vidaur, L., Planas, K., Sierra, R., Dimοpoulos, G., Ramirez, A., Lisboa, T. C., & Rello, J. (2008) · CHEST Journal · doi:10.1378/chest.07-2020 · Cited by 69
Velasco, E., & Bigni, R. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0546-y · Cited by 59
Chemaly, R. F., Hanmod, S. S., Jiang, Y., Rathod, D. B., Mulanovich, V. E., Adachi, J. A., Rolston, K. V. I., RAAD, I. I., & Hachem, R. Y. (2009) · Medicine · doi:10.1097/md.0b013e3181af01fc · Cited by 48
Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis
Mills, E. J., Perri, D., Cooper, C., Nachega, J. B., Wu, P., Tleyjeh, I. M., & Phillips, P. (2009) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-8-23 · Cited by 42
Candidemia in patients with diabetes mellitus: epidemiology and predictors of mortality
Bader, M. S., Lai, S. M., Kumar, V., & Hinthorn, D. R. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410021126 · Cited by 42
Timing of Central Venous Catheter Exchange and Frequency of Bacteremia in Burn Patients
King, B. T., Schulman, C. I., Pepe, A. P., Pappas, P. A., Varas, R. P., & Namias, N. (2007) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e318159a40b · Cited by 41
Self-citationBar, K. J., Wisplinghoff, H., Wenzel, R. P., Bearman, G. M., & Edmond, M. B. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-145 · Cited by 41
Samonis, G., Kofteridis, D. P., Saloustros, E. S., Giannopoulou, K., Ntziora, F., Christidou, A., Maraki, S., & Falagas, M. E. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701765657 · Cited by 33
A time-motion study of registered nurses' workflow in intensive care unit remote monitoring.
Tang, Z., Mazabob, J. M., Weavind, L., Thomas, E. J., & Johnson, T. R. (2006) · PubMed · Cited by 32
Genodermatoses with profound malignant potential
Tokar, I. P., Fraser, M. C., & Bale, S. J. (1992) · Seminars in Oncology Nursing · doi:10.1016/0749-2081(92)90040-a · Cited by 5
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Self-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Self-citation
Metadata
- Authors
- Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group
- Affiliations
- University of Wisconsin–Madison (US)
- University of Alabama at Birmingham (US)
- The University of Queensland (AU)
- Rutgers, The State University of New Jersey (US)
- AstraZeneca (United States) (US)
- Wayne State University (US)
- Radboud University Nijmegen (NL)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-12
- Volume
- 54
- Issue
- 8
- Pages
- 1110-1122
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2134827411
- Cited by
- 793
- References
- 72
- Citations by year
- 2026: 20 · 2025: 46 · 2024: 46 · 2023: 45 · 2022: 42 · 2021: 64 · 2020: 81 · 2019: 46 · 2018: 71 · 2017: 69 · 2016: 58 · 2015: 62 · 2014: 60 · 2013: 54 · 2012: 28
- FWCI
- 45.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- invasive candidiasis, candidemia, antifungal therapy, echinocandins, central venous catheter removal, mortality, clinical cure, risk factors, immunosuppression, Candida tropicalis, APACHE II score
- MeSH terms
- Adult, Aged, Antifungal Agents, Catheterization, Central Venous, Female, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Withholding Treatment, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.